These possibilities underscore the need for additional laboratory studies, including surveying other SS patients for CTLA4-CD28 fusions, and, if found, consideration of emerging strategies for clinical trials in this rare cancer (Tan et al. This evidence concerns the gene CD28 and synovial sarcoma.